Overview

NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)

Status:
Completed

Trial end date:
2021-01-07

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see whether adding Nimorazole to standard radiotherapy benefits patients with locally advanced head and neck squamous cell carcinoma.

Phase:

Phase 3

Details

Lead Sponsor:

The Christie NHS Foundation Trust

Treatments:

Cetuximab
Nimorazole